Deze e-learning wordt aangeboden in samenwerking met de University of Arizona. De kwaliteit is hoogstaand en er wordt gewerkt met verschillende werkvormen (interactieve casuistiek, quizen en video). De geschatte tijdsinvestering is 9 uur. Alle onderdelen zijn engels, zo ook de toelichting hieronder.
Over the past decade, interest in psychedelic medications and psychedelic plant and fungal medicines has steadily increased, as has their use in a growing number of clinical settings. While many of these substances are illegal in the United States, some are currently being researched for their potential benefit in mental healthcare and at end of life.
The Andrew Weil Center for Integrative Medicine has created this psychedelic course to give clinicians a broad overview of this topic and the current state-of-affairs. This is not a primer on how to prescribe or recommend psychedelic substances. This course will cover a variety of psychedelic substances that have been and/or are currently being investigated for their potential therapeutic value.
Course objectives:
- Describe the historical and cultural origins of psilocybin, MDMA, ibogaine, and ayahuasca.
- Define the potential mechanisms of action of psilocybin, MDMA, ketamine, ibogaine, and ayahuasca.
- Review the clinical evidence for effectiveness of MDMA, ketamine, psilocybin, ibogaine, and ayahuasca for mental health issues and end of life care.
- Describe the legality (including experimental use) of psychedelic medicines and substances, including MDMA, ketamine, psilocybin, ibogaine, and ayahuasca in the US.
- Review the role of set and setting, integration and the critical window theory within the context of therapeutic psychedelics.
Completion Requirements
Complete all the course work, course evaluation, and the final test with a score of 70% or better. Upon successful completion you will be able to print your certificate of completion.
Curriculum
SECTION I: An Overview & History
- Psychedelics – An Introduction
- First Wave Psychedelic Research to Reemergence
- Traditional Uses and Cultural Perspectives of Psychedelics
SECTION II: Modern Approaches: Psychedelic Research and Practice
- MDMA- and Ketamine-Assisted Therapies
- Psilocybin-assisted Therapies Research
- Ibogaine for Substance-misuse Treatment
- Ayahuasca
- Mechanisms of Therapeutic Psychedelics
- Emotional Regulation and Role of Spirituality in Psychedelic Research
SECTION III: Inclusive Therapeutic Approach
- Diversity, Equity, and Inclusion in Psychedelic Medicine
Target Audience
Primary Care Physicians, Internal Medicine Physicians, Pain Specialists, Psychiatrists, Nurse Practitioners, Physician Assistants
Inschrijving
Je kunt de e-learning online bestellen. Binnen 3 werkdagen ontvang je via de mail de inlogcodes en kun je aan de slag. Bij de afronding van de e-learning ontvang je direct per mail je certificaat. Op het moment van inschrijving heb je 30 dagen om de e-learning af te ronden. Deze periode kan altijd kosteloos met 30 dagen extra worden verlengd.
Accreditatie:
Er is zijn geen accreditatiepunten aan deze e-learning verbonden.
Organisatie nascholing:
Drs. Simone Ardesch
Voor informatie mail: marieke@schoolforintegrativemedicine.nl
Voorwaarden:
Voor deze scholing zijn de algemene voorwaarden van de ASIMH van toepassing
Course objectives:
- Describe the historical and cultural origins of psilocybin, MDMA, ibogaine, and ayahuasca.
- Define the potential mechanisms of action of psilocybin, MDMA, ketamine, ibogaine, and ayahuasca.
- Review the clinical evidence for effectiveness of MDMA, ketamine, psilocybin, ibogaine, and ayahuasca for mental health issues and end of life care.
- Describe the legality (including experimental use) of psychedelic medicines and substances, including MDMA, ketamine, psilocybin, ibogaine, and ayahuasca in the US.
- Review the role of set and setting, integration and the critical window theory within the context of therapeutic psychedelics.
Completion Requirements
Complete all the course work, course evaluation, and the final test with a score of 70% or better. Upon successful completion you will be able to print your certificate of completion.
Curriculum
SECTION I: An Overview & History
- Psychedelics – An Introduction
- First Wave Psychedelic Research to Reemergence
- Traditional Uses and Cultural Perspectives of Psychedelics
SECTION II: Modern Approaches: Psychedelic Research and Practice
- MDMA- and Ketamine-Assisted Therapies
- Psilocybin-assisted Therapies Research
- Ibogaine for Substance-misuse Treatment
- Ayahuasca
- Mechanisms of Therapeutic Psychedelics
- Emotional Regulation and Role of Spirituality in Psychedelic Research
SECTION III: Inclusive Therapeutic Approach
- Diversity, Equity, and Inclusion in Psychedelic Medicine
Joe Tafur, MD; Family Physician at Ocotillo Center for Integrative Medicine in Phoenix, Arizona; Fellow at the University of Arizona’s Center for Integrative Medicine; Co-founded the Church of the Eagle and the Condor (CEC); Co-founder of Modern Spirit
Ann Marie Chiasson, MD, MPH, CCFP; Director, Fellowship in Integrative Medicine, Andrew Weil Center for Integrative Medicine, University of Arizona
Josephine Begay-James, BS, MA; Diné (Navajo) Elder; Developed cultural school curriculums for K-12 school districts in Arizona and taught Diné language and Diné history and government for 34 years
Anthony Bossis, PhD; Clinical Psychologist and Clinical Assistant Professor of Psychiatry at NYU Grossman School of Medicine; Adjunct Professor of Classics and Religious studies at the University of Ottawa; Investigator at The Lundquist Institute for Biomedical Innovation
Rick Doblin, PhD; Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS). His conflict of interest has been mitigated via peer review by the activity director (CME) to ensure a fair/balanced presentation.
Gul Dolen, MD, PhD; Associate Professor in the Department of Neuroscience at the Johns Hopkins University, School of Medicine. Her conflict of interest has been mitigated via peer review by the activity director (CME) to ensure a fair/balanced presentation.
Belinda Eriacho, MPH, MT; Wisdom Carrier; Healer; Founder of Kaalogii LLC, focused on cultural and traditional teaching, inner healing, and an international speaker on various topics impacting Native American communities in the United States
Veronika Gold, LMFT; Co-founder and a CEO at Polaris Insight Center; Ketamine Assisted Therapy (KAP) therapist, consultant, and lead trainer; Sub-investigator and Therapist at MAPS sponsored MDMA-Assisted Therapy (MDMA-AT) for PTSD treatment Clinical Trials; Supervisor and Assistant Trainer for MDMA-AT
Bruno Gomes, PhD; Member of the Interdisciplinary Cooperation for Ayahuasca Research and Outreach (ICARO)-UNICAMP; Member of Chac runa Institute’s Ayahuasca Community Committee
Rachel Harris, PhD; Psychologist with both a research and a clinical background; Worked in private psychotherapy practice for thirty-five years specializing in people interested in psychospiritual development; Worked as a psychological consultant to Fortune 500 companies including the UN
Adele Lafrance, PhD; Clinical Psychologist, Research Scientist, Author, and Developer of Emotion-focused Treatment Modalities; Strategy Lead for the MAPS-sponsored study of MDMA-assisted psychotherapy for eating disorders; Clinical Trainer and Supervisor for Imperial College Center for Psychedelic Research
David Nutt, DM, FRCP, FRCPsych, FSB, FMedSci; Professor of Neuropsychopharmacology and Director of the Centre for Psychedelic Research at Imperial College London; Chief Research Officer of Awakn Life Sciences corp. His conflict of interest has been mitigated via peer review by the activity director (CME) to ensure a fair/balanced presentation.
Michael Pollan, MA; Writer, Teacher, and Activist; Professor in the English department at Harvard and at UC Berkeley’s Graduate School of Journalism
Scott Shannon, MD; Serves as a site Principal Investigator and therapist for the Phase III trial of MDMA assisted psychotherapy for PTSD sponsored by Multidisciplinary Association for Psychedelic Studies (MAPS); Past President of the American Holistic Medical Association; Past President of the American Board of Integrative Holistic Medicine. His conflict of interest has been mitigated via peer review by the activity director (CME) to ensure a fair/balanced presentation.
Nicholas Spiers, MA; Anthropologist; Research Coordinator at The Chac runa Institute
Rick Strassman, MD; Adjunct Associate Professor of Psychiatry at the UNM School of Medicine
Monnica Williams, PhD; Associate Professor in the School of Psychology at the University of Ottawa, Canada Research, Chair in Mental Health Disparities, and Director of the Laboratory for Culture and Mental Health Disparities; Clinical Director of the Behavioral Wellness Clinic, LLC in Tolland, Connecticut and Founded clinics in Kentucky, Virginia, and Pennsylvania. Her conflict of interest has been mitigated via peer review by the activity director (CME) to ensure a fair/balanced presentation.